AB
Ambrosia Biosciences
United States · Biotech · AI · Healthtech
Drug-discovery company developing oral small-molecule treatments for obesity and metabolic disorders.
Designing medicines around metabolic receptors
Ambrosia Biosciences develops orally delivered small molecules for obesity and other metabolic conditions. Its discovery programmes target metabolic receptors, including GLP-1, GIP and amylin, with the aim of developing medicines that can be used alone or in combinations.
The company combines structural biology, computational molecular design, chemistry and laboratory assays to identify and refine drug candidates. Its pipeline remains in discovery and preclinical development, with the lead oral GLP-1 programme advancing through work required before clinical evaluation.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series B | $100M | Blue Owl Healthcare Opportunities — LeadDeep Track Capital — LeadRedmile — LeadBoulder Ventures — ParticipantBVF Partners — ParticipantJanus Henderson Investors — ParticipantSamsara BioCapital — Participant |